|
|
|
|
|
|
by pepperberg
1845 days ago
|
|
|
You’re right, they completely differ from each other (regarding their relevance) and should therefore face an adjusted amount of scrutiny. If you’re one of the top pharmaceutical companies in the world, some press releases and study protocols are simply not enough [1] and should be (imo) discarded. If you’re a new player (Vaxxas) claiming “complete protection” by testing your product on mice, it’s simply not enough and should be (imo) discarded. [1] https://blogs.bmj.com/bmj/2020/11/26/peter-doshi-pfizer-and-... |
|
|